Login to Your Account

Still 'Dramatically Restrictive'?

Opinion Split On CMS' Revised Payouts For ESAs In Oncology

By Randall Osborne

Wednesday, August 1, 2007
Widespread outrage over proposed reimbursement changes for anemia drugs in oncology pushed the Centers for Medicare & Medicaid Services to a less severe final decision, but some onlookers proved more sanguine than others about the future of Amgen Inc.'s franchise - and would-be competitors continued to line up. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription